Natriuretic Peptides in Heart Failure with Preserved Ejection Fraction

Heart Failure Clinics

Volumn 10, Issue 3, 2014, Pages 453-470

  Richards, A Mark ^a,b   Januzzi, James L ^c   Troughton, Richard W ^b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

B type natriuretic peptide; Cardiac natriuretic peptides; Diagnosis; Heart failure; N terminal prohormone B type natriuretic peptide; Prognosis

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; IRBESARTAN; SPIRONOLACTONE; VALSARTAN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER;

ACUTE HEART FAILURE; ARTERIAL PRESSURE; BODY MASS; CARDIOVASCULAR MORTALITY; DIAGNOSTIC ACCURACY; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; GLOMERULUS FILTRATION RATE; HEART CATHETERIZATION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; ACUTE DISEASE; AGED; BLOOD; CARDIAC OUTPUT, LOW; CASE CONTROL STUDY; CHRONIC DISEASE; COMPARATIVE STUDY; FEMALE; HEART FAILURE; HEART STROKE VOLUME; MALE; MIDDLE AGED; PHYSIOLOGY; REFERENCE VALUE; SYNDROME;

ACUTE DISEASE; AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CARDIAC OUTPUT, LOW; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; STROKE VOLUME; SYNDROME;

EID: 84903480488     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2014.04.006     Document Type: Review

References (48)

1. Espiner E.A., Richards A.M. Atrial natriuretic peptide. An important factor in sodium and blood pressure regulation. Lancet 1989, 333:707-710.
2. O'Connor C.M., Starling R.C., Hernandez A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. NEngl J Med 2011, 365:32-43.
3. Saito Y. Roles of atrial natriuretic peptide and its therapeutic use. JCardiol 2010, 56:262-270.
4. Mentzer R.M., Oz M.C., Sladen R.N., et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery. The NAPA trial. JAm Coll Cardiol 2007, 49:716-726.
5. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33:1787-1847. 10.1093/eurheartj/ehs104.
6. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2013, 128:e240-e327. 10.1161/CIR. 0b013e31829e8776.
7. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. NEngl J Med 2002, 347:161-167.
8. Januzzi J.L., van Kimmenade R., Lainchbury J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients the International Collaborative of NT-proBNP Study. Eur Heart J 2006, 27:330-337.
9. Masson S., Latini R., Anand I.S., et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the valsartan heart failure (Val-HeFT) data. Clin Chem 2006, 52:1528-1538.
10. Komajda M., Carson P.E., Hetzel S., et al. Factors associated with outcome in heart failure with preserved ejection fraction findings from the irbesartan in heart failure with preserved ejection fraction study (I- PRESERVE). Circ Heart Fail 2011, 4:27-35.
11. Anand I.S., Rector T.S., Cleland J.G., et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 2011, 4:569-577.
12. Lainchbury J.G., Troughton R.W., Strangman K.M., et al. N-terminal Pro-B-type natriuretic peptide-guided treatment for chronic heart failure results from the BATTLESCARRED (NT-proBNP-assisted treatment to lessen serial cardiac readmissions and death) trial. JAm Coll Cardiol 2010, 55:53-60.
13. Pfisterer M., Buser P., Rickli H., et al. (TIME-CHF) randomized trial elderly patients with congestive heart failure the trial of intensified vs standard medical therapy in BNP-guided vs symptom-guided heart failure therapy. JAMA 2009, 301:383-392.
14. Savarese G., Trimarco B., Dellegrottaglie S., et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One 2013, 8:58287. 10.1371/journal.pone.0058287.
15. Troughton R.W., Frampton C.M., Brunner-La Rocca H.P., et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J 2014, 10.1093/eurheartj/ehu090.
16. O'Meara E., de Denus S., Rouleau J.-L., et al. Circulating biomarkers in patients with heart failure and preserved ejection fraction. Curr Heart Fail Rep 2013, 10:350-358.
17. Cheng J.M., Akkerhuis K.M., Battes L.C., et al. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail 2013, 15:1350-1362.
18. Maisel A.S., McCord J., Nowak R.M., et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction results from the breathing not properly multinational study. JAm Coll Cardiol 2003, 41:2010-2017.
19. Januzzi J.L., Camargo C.A., Anwaruddin S., et al. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol 2005, 95:948-954.
20. O'Donoghue M., Chen A., Baggish A.I., et al. The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. JCard Fail 2005, 11(Suppl 5):S9-S14.
21. Troughton R.W., Prior D.L., Pereira J.J., et al. Plasma BNP levels in systolic heart failure: the importance of left ventricular diastolic and right ventricular function. JAm Coll Cardiol 2004, 43:416-422.
22. Troughton R.W., Richards A.M. B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. JACC Cardiovasc Imaging 2009, 2:216-225.
23. Jaubert M.P., Armero S., Bonello L., et al. Predictors of B-type natriuretic peptide and left atrial volume index in patients with preserved left ventricular systolic function: an echocardiographic-catheterization study. Arch Cardiovasc Dis 2010, 103:3-9.
24. Iwanaga Y., Nishi I., Furuichi S., et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure comparison between systolic and diastolic heart failure. JAm Coll Cardiol 2006, 47:742-748.
25. Kraigher-Krainer E., Shah A.M., Gupta D.K., et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. JAm Coll Cardiol 2014, 63:447-456.
26. Richards A.M., Di Somma S., Mueller C., et al. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the biomarkers in acute heart failure (BACH) study. JACC Heart Fail 2013, 1:192-199.
27. Linssen G.C., Rienstra M., Jaarsma T., et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur heart J 2011, 13:1111-1120.
28. McKelvie R.S., Komajda M., Mc Murray J., et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. JCard Fail 2010, 16:128-134.
29. Anjan V.Y., Loftus T.M., Burke M.A., et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol 2012, 110:870-876.
30. Hildebrandt P., Collinson P.O., Doughty R.N., et al. Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cutpoint for ruling out suspected systolic dysfunction in primary care. Eur Heart J 2010, 31:1881-1889.
31. Costello-Boerrigter L.C., Boerrigter G., Redfield R.M., et al. Amino-terminal Pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community. Determinants and detection of left ventricular dysfunction. JAm Coll Cardiol 2006, 47:345-353.
32. Mason J.M., Hancock H.C., Close H., et al. Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the heart failure in care homes (HFinCH) diagnostic accuracy study. PLoS One 2013, 8:e53560.
33. Paulus W.J., Tschöpe C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28:2539-2550.
34. Sudoh T., Kangawa K., Minamino N., et al. Anew natriuretic peptide in porcine brain. Nature 1988, 332:78-81.
35. Hunt P.J., Yandle T.G., Nicholls M.G., et al. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995, 214:1175-1183.
36. Wang T.J., Larsen M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. NEngl J Med 2004, 350:655-663.
37. McDonagh T.A., Cunningham A.D., Morrison C.E., et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001, 86:21-26.
38. Baptista R., Jorge E., Sousa E., et al. Btype natriuretic peptide predicts long-term prognosis in a cohort of critically ill patients. Heart Int 2011, 6:e18. 10.4081/hi. 2011.e18.
39. Kucher N., Printzen G., Goldhaber S.Z. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003, 107:2545-2547.
40. Hsich E.M., Grau-Sepulveda M.V., Hernandez A.F., et al. Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with in-hospital outcomes: findings from the Get with the Guideline-Heart Failure registry. Am Heart J 2013, 166:1063-1071.
41. Fonarow G.C., Peacock W.F., Phillips C.O., et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. JAm Coll Cardiol 2007, 49:1943-1950.
42. van Veldhuisen D.J., Linssen G.C., Jaarsma T., et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. JAm Coll Cardiol 2013, 61:1498-1506.
43. Latini R., Masson S., Anand I., et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004, 25:292-299.
44. Maeder M.T., Rickenbacher P., Rickli H., et al. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the trial of intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Eur J Heart Fail 2013, 15:1148-1156.
45. Maisel A., Barnard D., Jaski B., et al. Primary results of the HABIT trial (heart failure assessment with BNP in the home). JAm Coll Cardiol 2013, 61:1726-1735.
46. Edelmann F., Wachter R., Schmidt A.G., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction. The Aldo-DHF randomized controlled trial. JAMA 2013, 309:781-791.
47. Solomon S.D., Zile M., Pieske B., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012, 380:1387-1395.
48. Desai A.S., Lewis E.F., Li R., et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011, 162:966-972.